Arrakis Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 8:30 a.m. ET.
About Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts. For more information, please visit www.arrakistx.com and engage with us on Twitter @ArrakisTx or on LinkedIn.
Today, RaySearch Laboratories AB (publ) publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.
This information is information that RaySearch Larboratiories AB...
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website.
"Implantica had a very...
Highlights
Underlying sales growth excluding OPM1 and Strategic Review2 of 3%.
Strong operational progress in all divisions and continued execution momentum across our 2024 strategic priorities.
Continuing to infuse our products with AI and...
With the return of French Days, Tineco is pulling out all the stops with unbeatable deals. French Days run from April 30 to May 7, 2024 on Cdiscount.
Tineco Floor One S5 COMBO meets all your vacuuming and cleaning needs! Featuring an innovative...
First quarter 2024
3 per cent organic revenue growth (using fixed exchange rates and a comparable group structure)Net sales increased by 1 per cent to 1,299.9 MEUR (1,286.6)Net sales including the reduction of acquired deferred revenue amounted to...
Xiao-I Corporation ("Xiao-I" or "the Company"), a leading artificial intelligence company, announced today that that the Company's full year 2023 financial results will be released before the U.S. market opens on Tuesday April 30, 2024.
The Company...
